Back to Authors

Cai, Meina

0009-0005-2079-1000

Mayo Clinic

Mayo Clinic Rochester, MN United States.

Citations 1

The first-in-class SFK ‘OFF’ inhibitor NXP900 suppresses YAP signaling and demonstrates tumor growth suppression in cholangiocarcinoma

Clinical Cancer Research | November 20, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1158/1078-0432.ccr-26-0849 | PMID 43063487

Abstract Purpose: Cholangiocarcinoma (CCA) is an aggressive malignancy with limited targeted therapeutic options and few validated strategies for molecular patient stratification. Src family kinases (SFKs) and YAP signaling contribute to CCA progression, but prior approaches to therapeutically target this axis have shown limited efficacy. Here, we evaluate the preclinical therapeutic potential of NXP900, a first-in-class SFK ‘OFF’ inhibitor, in CCA. Experimental Design: The antitumor activity of NXP900 was assessed across CCA cell lines, syngeneic murine models, and patient-derived xenografts (PDXs). Mechanistic studies examined the impact of SFK ‘OFF’ inhibition on YAP signaling. Integrated transcriptomic and proteomic analyses were used to identify molecular features associated with response and resistance. Results: NXP900 demonstrated decreased tumor cell viability in CCA cell lines and significant tumor growth suppression in PDX models. SFK ‘OFF’ inhibition suppressed YAP signaling through dual mechanisms involving inhibition of YAP Y357 phosphorylation and activation of Hippo pathway signaling. NXP900 enhanced the efficacy of gemcitabine and cisplatin, supporting its potential use in combination regimens. Multiomic analyses identified enrichment of sensitivity to NXP900 in IDH-mutant CCA models, defining a clinically actionable molecular subset. In addition, resistance to SFK ‘OFF’ inhibition was associated with activation of an IL13RA2-AKT signaling axis, which was pharmacologically targetable, providing a rational framework for combination strategies. Conclusions: These findings establish SFK ‘OFF’ inhibition with NXP900 as a promising therapeutic strategy in CCA and support biomarker-guided clinical evaluation, including in molecularly defined patient subsets and in combination with standard chemotherapy.